Indalo’s lead drug candidate, IDL-2965, is an oral, selective RGD-binding integrin antagonist of avb1, avb3, and avb6 that uniquely inhibits multiple processes of pathologic fibrosis, including the local activation of TGF-b by both epithelial cells and fibroblasts, as well as the ability of stiff extracellular matrix to promote fibroblast migration and survival.

In early 2019 Indalo initiated an adaptive Phase 1/2a program that enables assessment of safety, pharmacokinetic (PK), and biomarker-based proof of mechanism in NASH and IPF patients.

Rat liver fibrosis from CCl4 with and without treatment with IDL-2965.